The Virus With a Second Job

A herpes virus usually arrives without an invitation. At Virogin Biotech, the invitation is engineered. The Canadian company is redesigning HSV-1 - the virus better known for cold sores - so that it can enter a tumor, break cancer cells apart and leave behind signals that may help the immune system see what it missed. It is a strange career change for a pathogen. It is also an unusually concrete answer to a stubborn question in cancer medicine: how do you make a tumor that shrugs off treatment become visible again?

The medicine that makes an entrance

Virogin was founded in Canada in 2015 by Chris Huang and William Jia. Huang runs the company; Jia leads its science. Their first clinical candidate, VG161, begins with a weakened HSV-1 backbone. Researchers deleted a gene associated with the virus's ability to cause neurological harm, then equipped it with immune-modulating cargo: IL-12, IL-15, the IL-15 receptor alpha component, and a peptide designed to block PD-L1. The goal is to do two jobs at once. The virus can kill infected cancer cells directly. Its cargo may also change the neighborhood around those cells, where tumors often suppress immune attack.

That neighborhood is the real adversary. A cancer cell does not need to beat the entire immune system; it needs to make its immediate surroundings unwelcoming to immune cells. Checkpoint drugs can release one brake, but not every tumor has an immune response ready to accelerate. Virogin's hypothesis is that local viral treatment can supply the missing disturbance. The drug is injected into a tumor under imaging guidance. If the wider immune system learns from what happens there, even tumors outside the injection site might be affected. That last step is the promise, not a settled clinical result.

The number and the asterisk

In March 2025, a multicenter Phase 1 study of VG161 in refractory liver cancer was published in Nature. Among 34 patients with treatment-refractory hepatocellular carcinoma in the company's reported analysis, 17.65% had an objective response and 64.71% had disease control. Median overall survival was 9.4 months. The paper reported no dose-limiting toxicities and described changes in the tumor immune microenvironment. These are meaningful observations in people whose cancer had already resisted treatment.

The asterisk is just as important as the number. This was an early, small study, and the survival comparison often quoted for VG161 comes from historical or real-world controls, rather than patients randomly assigned in the same trial. Such comparisons can mislead when patient histories and subsequent treatments differ. The result explains why the program deserves further study; it cannot by itself establish that VG161 lengthens life. For patients and clinicians, that distinction is the difference between a reason to enroll in a trial and a treatment recommendation.

Regulators have given the program markers of interest, not a marketing license. The US FDA granted VG161 orphan-drug designation for intrahepatic cholangiocarcinoma and Fast Track designation for advanced hepatocellular carcinoma in 2023. China's drug regulator granted it breakthrough-therapy designation for advanced hepatocellular carcinoma in 2024. Each can help the development process; none makes the product approved.

“Virotherapy to Ignite Immunotherapy”Virogin's company tagline is unusually literal.

The virus gets a successor

Virogin did not stop at weakening HSV-1. Its second-generation candidate, VG201, uses a different control scheme. A tumor-associated promoter governs one essential viral gene, while microRNA regulation helps suppress another in normal cells. This is the company's answer to a familiar engineering compromise: weaken a virus for safety and it may lose some of its power to replicate in a tumor. VG201 aims to preserve antitumor activity while controlling where that activity happens. It carries IL-12 and IL-15-related immune payloads and has been studied by intratumoral injection in early trials. Virogin has also received Chinese authorization to investigate intravenous dosing, a potentially different way to reach tumors.

The company reported preliminary VG201 data at ASCO 2023: 18 dosed patients, a 67% disease-control rate at the poster cutoff, and no dose-limiting toxicities. Those figures are too early to rank the drug against other treatments. They do explain its next experiment. In April 2025, Virogin announced a collaboration with Akeso to study VG201 alongside ivonescimab, Akeso's bispecific antibody, in colorectal cancer that has spread to the liver. If the virus can make the tumor more receptive to immune attack, the antibody might have more to work with. That remains a trial question.

A vaccine before the virus?

There is a second half to Virogin's plan. Its mRNA platform includes discovery-stage vaccine programs for HPV, HER2-positive tumors, Epstein-Barr-virus-linked tumors and mpox, as well as work on self-amplifying RNA. The proposed cancer strategy is called prime-boost: use an mRNA vaccine to prime T cells against a target, then use an oncolytic virus to boost immune activity in the tumor. It is an elegant sequence on paper. Virogin has published preclinical work on HPV and HER2 approaches, but the combined strategy still needs clinical proof.

For a biotech partner, the practical attraction is a pair of platforms with different jobs: one can specify an immune target, the other can carry an inflammatory message into a tumor. For patients, there is no product to request at a pharmacy. Access, where available, is through trials with eligibility rules and clinical oversight. The company's commercial plan is to take candidates to early clinical proof of concept and license them or develop them with partners. Its VG161 arrangement with CNBG, a Sinopharm subsidiary, gives the partner development and commercialization rights in Greater China while Virogin keeps rights elsewhere. A five-year collaboration announced with MD Anderson in 2022 added clinical research infrastructure and a search for biomarkers that might identify likely responders.

What the experiment really costs

Drug development has a way of making a clever idea expensive. Virogin announced a US$62 million Series C round in 2020, an US$80 million D1 round in 2021, and a US$127 million D2 round later that year. The stated uses included VG161 trials, next-generation viral research, mRNA work, and manufacturing capacity. Those are financing amounts, not a price for treatment, and the company has not published a reliable per-patient cost. The more useful lesson for another biotech is procedural: build a mechanism that can be tested, earn human data, then use partnerships to run the more demanding experiments.

Oncolytic viruses have been appealing for years; their uneven clinical results are the warning in the room. Virogin's answer is to make the virus more selective, give it immune-stimulating cargo, pair it with other therapies and look for patients whose tumors show signs of responding. Whether that answer works will depend on reproducible benefit, manageable safety, and trials strong enough to separate a treatment effect from hopeful noise. The virus has a second job. The next studies must show whether it is good at it.

Keep reading

Follow the programs, trial records and company updates directly: